KẾT QUẢ HÓA TRỊ BỔ TRỢ PHÁC ĐỒ CAPOX Ở BỆNH NHÂN UNG THƯ DẠ DÀY TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Objectives: Evaluation of the efficacy of adjuvant chemotherapy with the CAPOX regimen and its adverse effects in gastric cancer patients at Thai Nguyen National Hospital. Method: Fifty-two gastric cancer patients at stage II and III received adjuvant chemotherapy with the CAPOX regimen following curative surgery at the oncology center of Thai Nguyen National Hospital from January 1, 2019, to June 30, 2024. Results: - The mean age of patients in our study was 60.4 ± 9.185 years. The male-to-female ratio was 3:1. Most patients were at Stage IIA, accounting for 32.7% of the study population. The median follow-up time was 33,958 ± 1,735 tháng. The 3-year disease-free survival rate was 76,7% and the 3-year overall survival rate was 87,2%. Completing 8 cycles of adjuvant chemotherapy had a significant impact on patient survival with p<0.05. - The most common hematologic adverse effects were neutropenia accounting for 40,4%, while the rate of patients with anemia, thrombocytopenia was 38,5% and 34,6%, primarily of mild severity (Grade 1 or 2). 78.8% and 53.8% of all patients had elevated AST and ALT, respectively and increased creatinine level was observed at the rate of 5.77%, with adverse effects predominantly of grade 1 or 2 severity. The most common side efect outside the hematopoietic system was paresthesia (50%). Other less common adverse effects included diarrhea (7.69%), nausea, and vomiting (28.84%), mostly of grade 1 or 2 severity. Conclusion: The median follow-up time was 34,586 ± 1,332 tháng. The disease-free survival and overall survival rates of patients in the study after 3 years were 76,7% and 87,2%, respectively. Completing the full 8 cycles of CAPOX chemotherapy significantly impacted patient survival with a p-value of <0.05. CAPOX adjuvant chemotherapy regimen is effective and safe with primarily grade 1 and 2 adverse effects.